AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Differences Between High-Sensitivity Cardiac Troponin T and Troponin I in Ambulatory Patients Starting Immune Checkpoint Inhibitor Therapy
By Ismail A, Vasbinder A, De Bever M et al.
Background: Immune checkpoint inhibitor (ICI) myocarditis remains the most feared cardiovascular complication after ICI initiation. Serial high-sensitivity cardiac troponin monitoring is recommended during ICI therapy to detect myocarditis, but guidelines do not specify whether troponin I (hs-cTnI) or troponin T (hs-cTnT) should be used. Unlike cardiac-specific hs-cTnI, hs-cTnT can rise from skeletal muscle, reduced renal clearance, and chronic myocardial turnover. Research Question: What are the kinetics of hs-cTnI and hs-cTnT in ICI-treated patients without myocarditis after ICI initiation? Methods: The Michigan Immunotherapy cardiovascular research study (MI-CARD) is a prospective single-center cohort of 433 ambulatory adults starting immune checkpoint inhibitor therapy, enrolled and followed with serial troponin measurement to characterize cardiovascular outcomes. In this cohort, we serially measured hs-cTnT and hs-cTnI at baseline and 1 month after ICI therapy initiation. For the purpose of this analysis, we excluded patients with ICI-associated myocarditis and myositis. We assessed discordance prevalence and temporal stability, clinical correlates, and the association of baseline biomarkers with all-cause mortality. Results: The cohort had a median age of 67 years, 55 % were male, and the most common malignancies were GU 18.9%, H&N/cutaneous SCC 17.3%, GI/hepatobiliary 15.5%, melanoma 13.4%, lung 13.4%. 74.6% of patients were treated with anti PD-1. The median hs-TnT and hs-TnI were 11 ng/L (IQR 6-19) and 2.5 ng/L (IQR 2.5-5.6), respectively. Among 433 patients with paired baseline measurements, hs-cTnT was elevated in 37.9% versus 1.8% for hs-cTnI; 158 (36.5%) showed a discordant pattern of elevated hs-cTnT with normal hs-cTnI, and agreement between assays was negligible (kappa=0.04). Discordance was present before ICI exposure and unchanged at 1 month (38.3% vs 38.0%; McNemar P=1.0). Independent correlates of discordance were older age, male sex, and chronic kidney disease (all P<0.05). Over a median 30.1 months, elevated baseline hs-cTnT predicted all-cause mortality (adjusted HR 1.37; 95% CI 1.02-1.83; P=0.038); however, only 8 of 230 deaths (3.5%) were cardiac-related. Conclusions: In ambulatory ICI-treated patients, more than one-third had elevated hs-cTnT with normal hs-cTnI, reflecting a stable, pre-existing, non-specific pattern that tracked comorbidity rather than cardiac injury. ICI therapy does not elevate troponin levels in non-myocarditis patients. Whether serial measurement of cardiac troponins impact outcomes in ICI-treated patients warrants further investigation